News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Clementia Pharmaceuticals Inc. Announces Key Leadership Appointments
World-class team with extensive orphan drug and rare disease experience to advance palovarotene into clinical development for the treatment of FOP MONTREAL, CANADA, January 29, 2014 (Marketwired)  —  Clementia Pharmaceuticals Inc. , a privately held clinical stage biotechnology company
View HTML
Toggle Summary Clementia Pharmaceuticals Inc. Announces Closing of $22.5 Million Series A Financing With Preeminent U.S. and Canadian Healthcare Venture Capital Funds
Company licenses exclusive world-wide rights to palovarotene from Roche Pharmaceuticals OrbiMed and BDC Venture Capital investment to advance palovarotene into clinical development for the treatment of FOP MONTREAL, CANADA, January 9, 2014 (Marketwired)  —  Clementia Pharmaceuticals Inc.
View HTML